Description:The SPDR S&P Biotech ETF seeks to replicate as closely as possible, before expenses, the performance of the S&P Biotechnology Select Industry Index (the "Index"). The Index represents the biotechnology sub-industry portion of the S&P Total Stock Market Index. The Index is one of nineteen (19) of the S&P Select Industry Indexes, each designed to measure the performance of a narrow sub-industry determined based on the Global Industry Classification Standards (GICS). The Index consists of the S&P Select Industry Indexes constituents belonging to the particular GICS sub-industry (e.g., biotechnology) that satisfy the following criteria: (i) rank within the 90th percentile of the float-adjusted market capitalization of the GICS sub-industry; (ii) are a U.S.-based company; and (iii) have a liquidity ratio greater than 60%. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index.
|SRPT||Sarepta Therapeutics Inc||3.05%|
|BIIB||Biogen Idec Inc||2.61%|
|DVAX||Dynavax Technologies Corp.||2.67%|
|VRTX||Vertex Pharmaceuticals Inc.||2.89%|
|BMRN||Biomarin Pharmaceutical Inc.||2.85%|
|UTHR||United Therapeutics Corp.||2.82%|
Data is provided by Zacks Investment Research